The basis for the differential sensitivity of cultured normal human mammary epithelial (HME) cells and a transformed human breast cancer MCF-7 cell line to growth inhibition by the isoflavone genistein and its 4'-methyl ether derivative, biochanin A, was examined. In HME cells genistein is 5-fold more potent as a growth inhibitor than biochanin A, whereas in MCF-7 cells biochanin A and genistein are equally potent as growth inhibitors. Based on its properties as an in vitro protein tyrosine kinase (PTK) inhibitor, biochanin A would be expected to be a less potent growth inhibitor than genistein. To determine whether isoflavone metabolism could account for the observed differences in growth inhibition, metabolism experiments were conducted with HME and MCF-7 cells using [4-l4 C]genistein and [4-14 C]biochanin A. MCF-7 cells extensively metabolized both isoflavones, producing two genistein metabolites with molecular weights of 350 and 380 and three biochanin A metabolites with molecular weights of 270, 350 and 380. In contrast, significant genistein or biochanin A metabolism was not observed in HME cells. Using mass spectrometry and nuclear magnetic resonance analysis, metabolite 350 from genistein and biochanin A experiments was identified as genistein 7-sulfate; biochanin A metabolite 270 was identified as genistein. Metabolite 380 was not unequivocally identified, but appeared to be a hydroxylated and methylated form of genistein sulfate. In MCF-7 cells, genistein 7-sulfate and metabolite 380 were detected primarily in the cell media fraction, suggesting that once formed these polar metabolites were excreted from the cells. These data show that isoflavone metabolism by transformed breast epithelial cells modulates the growth inhibitory effects of genistein and biochanin A. In MCF-7 cells, genistein metabolism was correlated with a decrease in growth inhibition, whereas biochanin A metabolism was associated with an increase in growth inhibition.
Introduction
In epidemiological studies, the consumption of soy isoflavones has been linked to decreased rates of several cancers, including breast and prostate cancer (1^4). Soy contains mg/g quantities of the isoflavones genistein (5,7,4'-trihydroxyisoflavone) and daidzein (7,4'-dihydroxyisoflavone) , which are present as their (J-glucoside conjugates (4) . Several mechanisms for the anticancer effects of genistein have been proposed (5) . These include topo-isomerase II inhibition (6) , induction of differentiation (7), inhibition of angiogenesis (8) , and inhibition of protein tyrosine kinase (PTK*) activity (9) .
PTK activity is critical for both normal and transformed cell growth (10). Therefore, compounds that inhibit PTK activity have been extensively investigated as potential anticancer agents (11, 12) . Furthermore, these compounds represent a novel class of drugs for pharmacologic intervention in the treatment and prevention of cancer that are directed against intracellular signaling components rather than DNA molecules (13) . These data led our laboratory, and others, to hypothesize that consumption of soy isoflavones may be responsible for the decreased rates of cancer in soy consuming populations (14) (15) (16) .
Although not present in soy foods, biochanin A (5,7-dihydroxy-4'-methoxyisoflavone) is an isoflavone closely related to genistein, differing only in a methoxy group at the 4' position. In cell-free assays, biochanin A inhibits PTK activity 30-fold less effectively than genistein (9) . However, in cell culture, biochanin A and genistein inhibit cancer cell growth approximately equally (17) (18) (19) . In vivo, biochanin A decreased lung tumor incidence and multiplicity when administered to benzo [a] pyrene-treated, non-inbred SwissWebster mice (20) . Furthermore, when administered in equal doses, biochanin A, but not genistein, inhibited the growth of several tumors derived from the human gastrointestinal tract and grown in BALB/c athymic nude mice (19) .
In addition, we have previously reported that genistein and biochanin A are 10-and 6-fold more potent inhibitors, respectively, of EGF-stimulated growth of normal human mammary epithelial (HME) cells than of MCF-7 transformed human breast cancer cells (21, 22, 23) . This increased sensitivity of non-transformed mammary epithelial cells to the inhibitory effects of genistein is consistent with its activity as a chemopreventive agent rather than a chemotherapeutic agent (5, 22) .
Although metabolism of isoflavones may largely occur in organs such as the liver, small intestine and kidney, isoflavone metabolism in the cells of the breast could explain the growth inhibitory action of biochanin A. It may also be responsible for the differential sensitivity of HME and MCF-7 cells to growth inhibition by genistein and biochanin A. Metabolism could influence isoflavone growth inhibition by altering the concentration or the chemical form of the isoflavones inside the cell.
In this study, the ability of HME and MCF-7 cells to metabolize [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]genistein and [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]biochanin A in cell culture was investigated. Radioactive metabolite peaks were isolated by HPLC; their identification was established by HPLC-mass spectrometry (HPLC-MS) and proton nuclear magnetic resonance spectroscopy ('H-NMR). The consequences of metabolism of genistein and biochanin A are discussed as they relate to growth inhibitory effects of these isoflavones on transformed and non-transformed mammary epithelial cells.
Materials and methods

Materials
A genistin concentrate (40-50% genistin by weight) was a gift of Protein Technologies International (St Louis, MO). Fetal bovine serum, tissue culture media, supplements and antibiotics were obtained from Gibco (Gaithersburg, MD), Clonetics (San Diego, CA) or Upstate Biotechnology (Lake Placid, NY). Tissue culture supplies were from Costar (Charlotte, NC). 3-<4,5-Dimethylthiazol-2-yl)-2,5Aliphenyl tetrazolium bromide (MTT), biochanin A, and sulfatase (from Aerobacter aerogenes, no pVglucuronidase activity) were from Sigma Chemical Co. (St Louis, MO). Pre-stained molecular weight standards and SDS-PAGE chemicals were from BioRad (Richmond, CA). Immobilon PVDF membranes and Sep-Pak C, 8 cartridges were from Millipore (Bedford, MA). Sephadex G-25 and LH-20 were purchased from Pharmacia (Piscataway, NJ). Aquapore reversed-phase C 8 columns were from Brownlee Labs (Santa Clara, CA). [4- 14 C]Genistein (23 mCi/mMol; 2.9 mg/ml) and [4- 14 C]biochanin A (23 mCi/mMol; 1.2 mg/ml) were custom synthesized by Moravek Biochemicals Incorporated (Brea, CA) and had a radiochemical purity by HPLC of >98%, as assessed by reversed-phase HPLC. Goat antirabbit horse-radish peroxidase labelled antibody and Lumi-glo enhanced chemiluminescence reagents were from Kirkegaard and Perry Laboratories (Gaithersburg, MD). All other reagents were of highest grade available.
Cell culture MCF-7 cells were a gift of Dr Craig Jordan (Northwestern University, Chicago, IL) and from the American Type Culture Collection (Rockville, MD). HME cells (strain 1001-7) were purchased from Clonetics Corporation (San Diego, CA). MCF-7 cells were maintained in Eagles modified essential media (EMEM), HEPES buffered, with 5% (v/v) fetal-bovine serum (FBS) and antibiotics (100 units/ml penicillin and 100 Ug/ml streptomycin). HME cells were maintained in mammary epithelial growth media (MEGM), containing 10 ng/ml epidermal growth factor (EGF), 5 Ug/ml insulin, 0.5 |ig/ml hydrocortisone, with 0.2% bovine pituitary extract and antibiotics (50 Ug/ml gentamicin and 50 ng/ml amphotericin B). MCF-7 cells were cultured as monolayers (passed every 6-8 days) in a 95% air. 5% CO2, water-saturated atmosphere. HME cells were maintained as described by the supplier.
Isoflavone isolation
Genistein was purified from genistin concentrate as described by Peterson and Barnes (17) . In brief, genistin was purified by fractional crystallization and then subjected to acid hydrolysis to produce genistein. Genistein was recovered from unhydrolyzed genistin by ether extraction and recrystallized twice from 80% aqueous ethanol. It was >98% pure as judged by its UV absorbance at 262 nm and by reversed-phase HPLC.
Metabolism studies
Cells were plated in 6-well plates and grown to 70% confluence. [4- l4 C]Biochanin A or [4-14 C]genistein were added to the cells at a final concentration of 1 ug/ml in 100% DMSO (0.5% v/v final [DMSO] concentration) (0.083 and 0.087 nCi/ml for biochanin A and genistein, respectively). Blank wells containing media and DMSO but no cells were used as controls. After incubation for the indicated times, media were collected and the cells were scraped and collected in 2 ml modified proteinase K buffer (25 mM EDTA, 137 mM NaCl and 10 mM Tris-HCl, pH 7.6). Cell lysates were sonicated and incubated with proteinase K (0.1 mg/ml) for 4 h at 37°C. Aliquots (100 ul) of media and lysates were sampled for radioactivity by scintillation counting. The remainder of the samples were passed through SepPak C 18 cartridges to collect the [4- 14 C]isoflavones and their metabolites. The cartridges were washed with 15 ml of distilled water to remove hydrophilic materials. Hydrophobic compounds were eluted with 10 ml of 80% aqueous methanol and dried at room temperature with air. Samples were resuspended in 100 \i\ 80% aqueous methanol and analyzed by reversed-phase HPLC.
HPLC analysis
Metabolites of [4- l4 C]genistein and [4-14 C]biochanin A were separated by reversed-phase HPLC using a Hewlett Packard model 1050 liquid chromatograph. Samples were injected onto a 30 cmX4.6 mm i.d. Aquapore C 8 column, which was eluted at a flow rate of 1 ml/min with a mobile phase consisting of a gradient of 0-45% acetonitrile (at 4.5%/min) in 0.1% (v/v) aqueous trifluoroacetic acid. Eluted substances were detected by their absorbance at 262 nm. The column eluatc was collected in 30 s fractions and counted to determine the location of radioactive peaks using a Packard 1900CA liquid scintillation spectrometer.
HPLC-mass spectwmelry (HPLC-MS)
Media extracts or individual radioactive metabolite peaks were analyzed by reversed-phase HPLC-mass spectrometry using a 10 cmX2.1 mm i.d. Aquapore C 8 column which was eluted at a flow rate of 0.2 ml/min with a gradient of 0-50% acetonitrile (at 5%/min) in 2 mM ammonium acetate. The column eluate was split 1:1 with 100 ul/min going to the electrospray lonization interface of an API in triple quadrupole mass spectrometer (PE-Sciex, Concord, Ontario, Canada); negative ion mass spectra were recorded using an orifice potential of -70 V.
Preparation of synthetic genistein sulfate Synthetic genistein sulfate was prepared by coupling genistein (0.1 mmol) with an equimolar amount of sulfuric acid in the presence of a 10-fold molar excess of dicyclohexylcarbodiimide in 1 ml anhydrous dimethylformamide at 4°C. After addition of water (5 ml) and removal of insoluble dicyclohexylurea by centrifugation (2500 g for 10 min), the supernatant fraction was applied to Sep-Pak Cj 8 cartridges as described in the Metabolism section. The 80% aqueous methanol eluates were not dried down, but immediately passed over 5 cmX 1.5 cm i.d. DEAE-Sephadex columns, previously prepared by washing DEAE-Sephadex with three volumes of 20, 50 and 100% aqueous methanol, followed by 10 volumes of 0.1 M NaOH, 70% aqueous methanol (two times), 0.5 M acetic acid and 70% aqueous methanol (two times). After loading the sample, the columns were washed with 15 ml 70% aqueous methanol, followed by 15 ml 0.2 M acetic acid (in 70% aqueous methanol). This step allowed unreacted genistein to pass through the column. Genistein sulfate was eluted with 0.5 M LiCl (in 70% aqueous methanol). This fraction was evaporated to dryness. Samples were resuspended in 10% aqueous methanol and loaded on to a 15 cmX3 cm i.d. Sephadex LH-20 column, pre-equilibrated in 10% aqueous methanol. The column was washed with 10% aqueous methanol for 30 min at a flow rate of 30 ml/h to remove LiCl and other non-absorbed compounds. Synthetic genistein sulfate was recovered by eluting the column with 30% aqueous methanol at 30 ml/h for 15 min. The fractions containing genistein sulfate were located by their absorbance at 262 nm, pooled, evaporated to dryness and stored at 4°C. Synthetic genistein sulfate was subjected to HPLC and HPLC-MS analysis as described above to assess its purity.
Enzymatic synthesis of genistein sulfate
Phenol sulfating form of human phenol sulfotransferase (P-PST) enzyme was purified as described by Falany et al. (24) . Briefly, Escherichia coli XL1-Blue cells containing cloned P-PST in the bacterial expression vector pKK233.2 were grown to an OD^ of 0.5, then induced by the addition of 0.15 mM IPTG and incubated for 2 h. Bacteria were pelleted and resuspended in bacterial lysis buffer (75 mM Tris-HCl, pH 8.0, 0.25 M sucrose, 0.25 mM EDTA, 0.02 mg/ml lysozyme) for 20 min at 4°C. Bacteria were repelleted and resuspended in triethanolamine (TEA) buffer (10 mM TEA, pH 7.5, 10% glycerol, 1.5 mM DTT, 10 (Ig/ml phenylmethylsulfonyl fluoride (PMSF) and sonicated (10 s, four times on ice). Bacterial cytosol was collected by centrifugation at 100 000 g for 45 min at 4°C. The cytosol was loaded onto a DEAE-Sepharose C1-6B (6X1 cm i.d.) column and the column was washed with 10 ml of 10 mM TEA buffer containing 0.23 mg/ml dithiothreitol. The column was next washed with 10 ml TEA buffer containing 100 mM NaCl and then P-PST was eluted with a gradient of 100-225 mM NaCl in TEA buffer. P-PST activity was measured by conversion of minoxidil to minoxidil sulfate (19) . Fractions containing P-PST activity were pooled and stored at -70°C.
Enzymatic genistein sulfate was prepared by incubating 850 |ig genistein in sulfation buffer (50 mM Tris-HCl, pH 7 4, 10 mM MgCl 2 , 50 uM 3'phosphoadenosine-5'-phosphosulfate (PAPS), and P-PST). The sulfation reaction was monitored by HPLC and terminated by the addition of acetic acid. Triethylammonium sulfate (300 mM) was added to the reaction mixture and genistein and genistein sulfate were recovered by absorption onto C 18 Sep-Pak cartridges as described previously. Genistein and genistein sulfate were separated and purified as described above for synthetic genistein sulfate.
Nuclear magnetic resonance spectroscopy
Genistein and the enzymatic and synthetic genistein sulfates (20-30 Jig) were dissolved in DMSO-d^O.S ml). 'H NMR spectra were obtained in overnight data collections (14 h) with a 6173-Hz sweep width, 2.65-s repetition rate, and 30° sweep angle on a Bruker ARX spectrometer (operating frequency of 300 MHz). Spectra were internally referenced to the DMSO proton resonance (2.49 p.p.m.).
Western blot analysis HME and MCF-7 cells were grown as described to 90% confluency. Media were aspirated and cells were lysed immediately in SDS/triton X-100 buffer (0.1% SDS, 1% tnton X-100, 137 mM NaCl, 1 mM PMSF, 1 ng/ml aprotinin, 1 Ug/ml leupeptin, 1 |ig/ml pepstatin A, 5 mM EDTA and 1 mM sodium orthovanadate). The plates were rocked at room temperature for 30 s and cells were scraped into microfuge tubes. The supernatant fraction was passed through a 21 gauge needle eight times to shear DNA and centrifuged for 10 min at 10 000 g. Protein concentrations were determined by the Lowry method (25) . Cell lysate proteins (800 ug) were resolved on 8% SDS-PAGE and transferred to nitrocellulose membranes. Immunoblot analysis of P-PST was performed using a rabbit anti-human P-PST antibody (1:10 000) (26) and visualized using enhanced chemiluminescence as described by the manufacturer (Kirkegaard and Perry Laboratories, Gaithersburg, MD).
Results
MCF-7 cells metabolize genistein and biochanin A
A metabolite peak (2G) was detected by scintillation counting of reversed-phase HPLC eluate fractions when [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]genistein was incubated with MCF-7 cells over a 4-day period ( Figure  1A ). This peak was not present when genistein was incubated in the presence of cell culture media alone without MCF-7 cells ( Figure IB ). An additional peak was observed by reversedphase HPLC using UV detection, but it was not radioactive, suggesting that the compound(s) in this peak originated from a cell media component, rather than genistein. Additionally, this peak was present when cells were in grown media alone in the presence or absence of DMSO (data not shown).
MCF-7 cells extensively metabolized biochanin A over a 4-day incubation, producing two new peaks (2B and 3B) (Figure 2A) . Again, none of these peaks were present when biochanin A was incubated in cell culture media in the absence of MCF-7 cells ( Figure 2B ). As for the experiments with genistein, an additional peak was observed by reversed-phase HPLC using UV detection and appeared to be derived from a cell media component (non-radioactive) (data not shown). Cochromatography experiments demonstrated that peaks 2B and 3B had the same HPLC mobility as peaks 2G, and genistein, respectively (data not shown). These data suggested that MCF-7 cells initially demethylated biochanin A, converting it to genistein. Once formed, genistein was then further metabolized by MCF-7 cells as described above. Similar results were obtained for genistein and biochanin A metabolism with four other transformed mammary epithelial cell lines (G.Peterson, G.-P.Ji, M.Kirk and S.Barnes, unpublished data).
The metabolites of genistein and biochanin A, peaks 2B and 2G, were found primarily in cell culture media fractions of MCF-7 cells, with trace amounts being recovered in cell lysate fractions (Figures 1C and 2C) . The amount of peaks 2B and 2G detected in the cell lysate fraction was at the limit of HPLC-UV sensitivity, but could be detected by scintillation counting of HPLC eluates. These data suggested that as soon as peaks 2B and 2G were formed, they were efficiently excreted from MCF-7 cells. Genistein and biochanin A were also detected in cell lysate fractions at levels roughly equivalent to that of peaks 2B and 2G ( Figures 1C and 2C ). In experiments with biochanin A, genistein was the primary isoflavone detected in the cell lysates ( Figure 2C ).
Identification of metabolites
Identification of the metabolites of genistein and biochanin A was carried out using a combination of reversed-phase HPLC-MS and NMR. Peak 2G when analyzed by reversed-phase HPLC-electrospray ionization-MS was composed of two dis- genistein (+80) corresponds to the addition of a single sulfate group. This was verified by the sensitivity of metabolite 350 to the hydrolytic action of sulfatase, but not glucuronidase (data not shown). Additionally, the product of the sulfatase reaction had the same HPLC retention time and MS-MS spectrum as authentic genistein ( Figure 4A and B) .
To further confirm that metabolite 350 was a genistein monosulfate, genistein sulfate was both chemically synthesized and prepared from an in vitro reaction using bacterially expressed and purified phenol sulfating form of human phenol sulfotransferase (P-PST). The principal synthetic genistein monosulfate had an HPLC retention time similar to, but different from, metabolite 350 ( Figure 5A ), whereas the minor synthetic genistein monosulfate had the same retention time as metabolite 350 ( Figure 5A ). On the other hand, the genistein sulfate produced enzymatically by the P-PST, migrated with the same retention time as metabolite 350 ( Figure 5B ). These data suggested that metabolite 350 and the P-PST-produced genistein sulfate were identical, while the principal synthetic genistein monosulfate was another genistein sulfate isomer.
To address the site of sulfate attachment in metabolite 350, the principal synthetic genistein sulfate, P-PST produced genistein sulfate, and genistein were analyzed by 'H-NMR. When the proton chemical shifts for the enzymatically produced genistein sulfate were compared with those for genistein, the Hg and H 8 proton resonances underwent chemical shift changes of 0.5 p.p.m. and the 7-OH resonance was absent, whereas the H 3 ' and H 5 ' proton resonances were unchanged (Table I) . These alterations to the 'H-NMR spectrum indicated that the enzymatically produced genistein monosulfate was the 7-isomer. On the other hand, when the proton chemical shifts for the principal synthetic genistein monosulfate and genistein were compared, the H3' and H5' proton resonances underwent chemical shift changes of 0.4 p.p.m. (Table I) , whereas the He and Hg proton resonances were unchanged, indicating that the sulfate is located at the 4-position in synthetic genistein sulfate.
Peak 3B from biochanin A metabolism experiments migrated with a retention time identical to that of genistein, suggesting that MCF-7 cells demethylated biochanin A and produced genistein. This was confirmed as peak 3B and genistein comigrated on HPLC ( Figure 6 ) and gave identical spectra in HPLC-MS experiments (data not shown).
HME cells do not metabolize genistein and biochanin A
In contrast to MCF-7 cells, HME cells did not significantly metabolize genistein ( Figure 7A and B) or biochanin A ( Figure  8A and B) over a 3-day incubation period, as judged by scintillation counting of HPLC eluates. Additionally, HPLC-UV detection did not detect metabolite formation, and HPLC-MS analysis of medium extracts confirmed HME cells did not produce significant quantities of the metabolites observed in media from experiments with MCF-7 cells (data not shown). In some experiments, minor peaks and traces of radioactivity were detected eluting at 8 to 9 min in HME cells, but the amount detected was always at least 20-fold lower than that observed in MCF-7 cells (data not shown). Similar results were obtained with batches of HME cell lines from different donors (Peterson and Barnes, unpublished data).
Significant quantities of genistein or biochanin A metabolites were not detected in HME cell lysates ( Figures 7C and 8C) . However, there was consistently more genistein and biochanin A in the cell lysate fraction from HME cells than from MCF-7 cells as judged by the amount of radioactivity recovered ( Figure 1C versus 7C and 2C versus 8C) .
Expression of P-PST correlates with genistein metabolism
Sulfotransferases are known to be expressed in breast tissue and to sulfate small planar molecules such as estrogens and estrogen-like compounds (i.e. genistein). A specific human sulfotransferase, P-PST, is expressed in MCF-7 cells (27) . Since metabolite 350 appeared to be identical to P-PSTproduced genistein sulfate, we investigated the expression of P-PST in MCF-7 and HME cells. Whole cell lysates of MCF-7 and HME cells were analyzed by Western blot analysis using a rabbit polyclonal anti-PST antibody (26) . A single band corresponding in molecular weight to recombinant P-PST, was detected in MCF-7 cells, but not in HME cells, and this band co-migrated with bacterially expressed P-PST ( Figure 9 ).
Discussion
These studies have shown that genistein and biochanin A are metabolized by MCF-7 cells, but not by HME cells. From the data presented, a general scheme of metabolism in MCF-7 cells has been deduced. Genistein is metabolized by MCF-7 cells, yielding two monosulfated metabolites derived from genistein, metabolite 350 and metabolite 380. Metabolism of biochanin A proceeds by a similar mechanism. As a first step in its metabolism, biochanin A is metabolized to genistein via a demethylation reaction and the generated genistein is metabolized further to metabolite 350. The sulfated metabolites are excreted from the cell, ultimately terminating the growth inhibitory effects of genistein. Therefore, metabolism may explain the effects of genistein and biochanin A on inhibition of MCF-7 and HME cell growth. The idea that isoflavones and PTK inhibitors themselves, undergo metabolism in target cells is not new. Evidence is accumulating that tyrphostins, synthetic PTK inhibitors, undergo metabolism in cells (28, 29) . This could explain the long incubation times necessary for tyrphostin action and the reported loss of in vitro specificity when analyzed in cell culture (29) . Substantial metabolism of genistein and biochanin A has also been observed in animals (30) and humans, although metabolism by specific cell types have not been previously reported. The predominant metabolite of genistein and biochanin A in MCF-7 cells is genistein 7-monosulfate, metabolite 350. Genistein has hydroxyl groups at the 5, 7 and 4' positions, which could serve as sites of sulfation to produce metabolite 350. NMR experiments conducted on metabolite 350 isolated from cell media to determine the position of sulfation did not settle this issue due to unresolvable contaminants in the cell media (data not shown). However, HPLC-MS and NMR studies with P-PST-derived and chemically synthesized genistein monosulfate strongly suggested that metabolite 350 was sulfated at the 7-position. This conclusion is supported by the apparent hydrophobicity of these genistein sulfates as compared to daidzein. The 5-hydroxyl group of genistein (and genistein 4'-and 7-sulfates) is located near a ketone oxygen at the 4'-position. These two groups form a hydrogen bond, giving genistein a more hydrophobic nature than expected, as demonstrated by its longer elution time than daidzein (which lacks the 5-hydroxyl group) on reversed-phase HPLC (31, 32) . Metabolite 350, even with the addition of a charged sulfate group, still elutes from reversed-phase HPLC more slowly than daidzein, indicating that the hydrophobic nature of the molecule is not altered. This alone suggests that sulfation does not occur at the 5'-position.
The structure of metabolite 380 is more complex, since in addition to sulfation, seven positions on the genistein molecule are potentially open for hydroxylation and two sites for methylation. Attempts to isolate enough metabolite 380 for NMR analysis have been unsuccessful.
Metabolism of genistein and biochanin A is important in understanding the inhibitory effects of these isoflavones on MCF-7 and HME cell growth. Genistein and biochanin A inhibit the growth of MCF-7 cells stimulated by fetal bovine serum with IC50 values of 9.7 and 7.0 |ig/ml, respectively (23). In contrast, HME cells stimulated by bovine pituitary extract are more sensitive to growth inhibition by genistein and biochanin A with VZ^ values of 0.9 and 3.3 |ig/ml, respectively (Peterson and Barnes, unpublished) . These data show that genistein and biochanin A are more potent inhibitors of HME cell growth than MCF-7 cell growth.
MCF-7 cell lysates contained low and variable amounts of genistein 7-sulfate (met 350), metabolite 380, genistein, and biochanin A as determined by scintillation counting of HPLC eluates. The majority of radioactivity, in the form of genistein 7-sulfate and metabolite 380, was found almost exclusively in MCF-7 cell media. Since 60-100% of biochanin A is converted to genistein, and 25-75% of genistein is converted to genistein 7-sulfate, the result of the excretion of genistein 7-sulfate is to maintain a lower concentration of genistein in MCF-7 cells.
In contrast, since no significant metabolism occurs in HME cells, the intracellular concentrations of genistein and biochanin A should be unaffected. HME cell lysates always contained more genistein and biochanin A than MCF-7 cell lysates, suggesting the intracellular isoflavone concentrations were higher in HME cells. The amount of genistein, biochanin A and genistein 7-sulfate detected in cell lysates could, in part, be the result of the non-specific binding of these compounds to the exterior of the cells and is not a true indicator of intracellular concentration. However, preliminary experiments showed HME cells do have higher intracellular concentrations than MCF-7 cells (Peterson, Kirk and Barnes, unpublished data).
These data suggest that the differential sensitivity of HME Minutes Fig. 8 . Reversed-phase HPLC of l4 C-radioactivity in HME cell culture media and lysate fractions. (A) Media from incubation of biochanin A with HME cells; (B) media from incubation of biochanin A in the absence of HME cells; and (C) cell lysate from incubation of biochanin A with HME cells. and MCF-7 cells to genistein and biochanin A growth inhibition could be due to the intracellular formation of genistein 7-sulfate and metabolite 380 and their excretion from MCF-cells. This hypothesis is consistent with the role of sulfation in terminating the biological effects of compounds (33) . In this mechanism, sulfation serves to signal the efflux of genistein from the cell.
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The metabolism of biochanin A to form genistein is also significant when the effect of biochanin A on the growth of HME and MCF-7 cells is examined. Biochanin A is a 30-fold less potent PTK inhibitor than genistein (9) . Biochanin A, however, is a more potent growth inhibitor of MCF-7 and human prostate cancer cells (17, 18, 22, 23) . Since at least 60-100% of the biochanin A added to MCF-7 cells is metabolized to genistein, adding biochanin A to MCF-7 cells is equivalent to adding genistein. Although the genistein is ultimately converted to genistein-7-sulfate and excreted, time course experiments show conversion of biochanin A to genistein occurs within 24 h, while conversion of genistein to genistein-7-sulfate is slower (genistein is present after 36 h). This suggests biochanin A-derived genistein has a significant residence time inside MCF-7 cells in which it can inhibit cell growth. The greater hydrophobicity of biochanin A compared with genistein (due to its methylation at the 4'-OH) may also augment its uptake into the cell and/or cellular distribution, facilitating genistein growth inhibition. The increased cytotoxicity of genistein in MCF-7 cells supports this hypothesis (23). Therefore, biochanin A metabolism to genistein provides an explanation for the increased effects of biochanin A on cell growth than would be expected from its in vitro PTK inhibitory activity. Since HME cells do not convert biochanin A to genistein, biochanin A is a weaker growth inhibitor than genistein. Similar metabolic conversions may be responsible for the action of biochanin A in other cell culture and animal models (19, 20) .
Breast epithelial cells express several types of sulfotransferases. Of the sulfotransferases in MCF-7 cells, only P-PST is capable of sulfating genistein in vitro (27) . The levels of P-PST in MCF-7 and HME cells (as determined by Western blot analysis) correlated with metabolism of genistein to genistein sulfate. These data strongly suggest that P-PST, or a very similar enzyme, is responsible for conversion of genistein to genistein sulfate in MCF-7 cells.
In summary, these data suggest the following model to explain the effects of metabolism on isoflavone growth inhibition. In MCF-7 cells, genistein is converted to two sulfated metabolites of genistein. These compounds do not remain inside the cell, but are rapidly excreted. The net result of this action is to lower the intracellular concentration of genistein, thereby decreasing its growth inhibitory actions. Therefore, higher extracellular genistein concentrations are needed to increase the intracellular genistein concentration to levels where growth inhibition is observed. In contrast, biochanin A is activated in MCF-7 cells by its metabolism to genistein. The genistein is slowly converted to genistein-7-sulfate, providing genistein sufficient time to inhibit MCF-7 cell growth. HME cells do not metabolize genistein or biochanin A. Therefore, higher intracellular isoflavone concentrations are reached in HME cells than in MCF-7 cells at equivalent extracellular concentrations, allowing growth inhibition to occur at lower isoflavone concentrations. Also, since biochanin A is not metabolized in HME cells, its effect on HME cell growth is less than that of genistein.
